右心衰竭幼龄大鼠B型钠尿肽的变化及卡维地洛的干预作用

摘要
图/表
参考文献(20)
相关文章 (1)
点击分布统计
下载分布统计

全文: PDF (1593 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的：通过研究右心衰竭幼龄大鼠血清B型钠尿肽（BNP）含量、右室心肌BNP蛋白和BNP mRNA 表达的变化及β受体阻滞剂卡维地洛的干预作用，探讨BNP在小儿右心衰竭的诊断和治疗中的意义。方法：51只Sprague Dawley 4周龄大鼠随机分为4周心衰组、6周心衰组、卡维地洛组、4周对照组和6周对照组。心衰组及卡维地洛组大鼠给予腹腔注射野百合碱（MCT），两个对照组给予腹腔注射生理盐水。至4周形成右心衰竭模型，将4周心衰组和4周对照组幼龄大鼠处死观察心肌病理学变化，同时卡维地洛组开始给予卡维地洛灌胃共14 d，6周心衰组和6周对照组同时等量蒸馏水灌胃至6周。每组存活大鼠测血流动力学和相关生理指标， ELISA法检测血清中的BNP水平，免疫组化法和RT-PCR法检测右室心肌BNP蛋白和BNP mRNA的表达。结果：4周心衰组血清BNP浓度、右室心肌中BNP蛋白、BNP mRNA与4周对照组相比均明显升高(P<0.01)，6周心衰组上述指标升高更为显著(P<0.01)。血清BNP、心肌BNP蛋白之间具有正相关关系(P<0.01)。卡维地洛组与6周心衰组比较血流动力学改善，右室肥厚减轻，血清BNP浓度、心肌中BNP蛋白和BNPmRNA表达均降低(P<0.05)。结论：右心衰竭时BNP可作为诊断和反映心衰严重程度的指标，卡维地洛对治疗压力负荷性右心衰竭有一定作用。［中国当代儿科杂志，2009，11（7）：571-576］

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	安金斗
	梁芳
	冯嵩

关键词 ：右心衰竭, B型钠尿肽, 卡维地洛, 幼龄大鼠

Abstract：OBJECTIVE: To examined serum B-type natriuretic peptide (BNP) levels and BNP expression of protein and mRNA in the right ventricular myocardium in juvenile rats with right heart failure (RHF) and the effects of β-adrenergic receptor blocker carvedilol on serum and myocardial BNP levels in order to investigate the role of BNP in the diagnosis and treatment of RHF. METHODS: Fifty-one four-week-old Sprague-Dawley rats were randomly assigned to 5 groups: RHF 1, RHF 2, carvedilol-treated RHF, control 1 and control 2. RHF was developed 4 weeks after an intraperitoneal injection of monocrotaline in the RHF 1, RHF 2 and carvedilol-treated RHF groups. The rats in the RHF 1 and the control 1 groups were sacrificed after the RHF event for observing pathological changes in the myocardium. After the RHF event, the carvedilol-treated group was given intragastric administration of carvedilol (3.5 mg/kg/d) for 2 weeks. The RHF 2 and the control 2 groups were given distilled water of equal dose instead. The rats were sacrificed 2 weeks after carvedilol or distilled water administration. Serum BNP levels were measured using ELISA. BNP protein and mRNA expression in the right ventricular myocardium were measured by immunohistochemistry and RT-PCR, respectively. Haemodynamics and some physiological indexes were measured. RESULTS: Serum BNP levels and BNP protein and mRNA expression in the right ventricular myocardium were significantly higher in the RHF 1 group than those in the control 1 group (P<0.01). Serum BNP levels and BNP protein and mRNA expression in the right ventricular myocardium increased more significantly in the RHF 2 group. There was a positive correlation between serum BNP levels and myocardial BNP protein expression in the RHF group (r=0.698, P<0.01). Serum BNP levels and BNP protein and mRNA expression in the carvedilol-treated RHF group were significantly reduced when compared with the RHF 2 group (P<0.05). Carvedilol treatment also resulted in improved hemodynamics and relieved right ventricular hypertrophy. CONCLUSIONS: BNP may serve an index for the diagnosis of RHF and the evaluation of severity in children with RHF. Carvedilol shows protections against RHF caused by pressure load.［Chin J Contemp Pediatr, 2009, 11 (7):571-576］

Key words： Right heart failure B-type natriuretic peptide Carvedilol Juvenile rats

PACS:

R-33

引用本文:

安金斗,梁芳,冯嵩. 右心衰竭幼龄大鼠B型钠尿肽的变化及卡维地洛的干预作用[J]. 中国当代儿科杂志, 2009, 11(07): 571-576.

AN Jin-Dou,LIANG Fang,FENG Song. B-type natriuretic peptide (BNP) levels and the effects of carvedilol on BNP levels in juvenile rats with right heart failure[J]. CJCP, 2009, 11(07): 571-576.

链接本文:

http://www.zgddek.com/CN/ 或 http://www.zgddek.com/CN/Y2009/V11/I07/571

	［1］Krüger S, Graf J, Merx MW, Koch KC, Kunz D, Hanrath P, et al. Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism［J］. Am Heart J, 2004, 147(1):60-65.
	［2］Qvigstad E, Sjaastad I, Bokenes J, Schiander I, Solberg L, Sejersted OM, et al. Carvedilol blockade of alpha1-and beta-adrenoceptor induced inotropic responses in rats with congestive heart failure［J］．Eur J Pharmacol, 2005, 516(1):51-59.
	［3］Dalla Libera L, Ravara B, Angelini A, Rossini K, Sandri M, Thiene G, et al. Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker irbesartan in experimental heart failure［J］. Circulation, 2001, 103(17):2195-2200.
	［4］Campian ME, Hardziyenka M, Michel MC, Tan HL. How valid are animal models to evaluate treatments for pulmonary hypertension?［J］. Naunyn Schmiedebergs Arch Pharmacol, 2006, 373(6):391-400.
	［5］于洋,张国伟,祁家驹.大鼠右心衰竭模型的建立［J］. 中国胸心血管外科临床杂志, 2007, 14（4）：288-291.
	［6］Liang YJ, Lai LP, Wang BW, Juang SJ, Chang CM, Leu JG, et al. Mechanical stress enhances serotonin 2B receptor modulating brain natriuretic peptide through nuclear factor-kappaB in cardiomyocytes［J］. Cardiovasc Res, 2006, 72(2):303-312.
	［7］Wang J, Marui A, Ikeda T, Komeda M. Partial left ventricular unloading reverses contractile dysfunction and helps recover gene expressions in failing rat hearts［J］. Interact Cardiovasc Thorac Surg, 2008, 7(1):27-31.
	［8］Pruszczyk P. N-terminal Pro-brain natriuretic peptide as an indicator of right ventricular dysfunction［J］. J Card Fail, 2005, 11(5 Suppl):S65-69.
	［9］Usui S, Yao A, Hatano M, Kohmoto O, Takahashi T, Nagai R, et al. Upregulated neurohumoral factors are associated with left ventricular remodeling and poor prognosis in rats with monocrotaline-induced pulmonary arterial hypertension［J］. Circ J, 2006, 70(9):1208-1208.
	［10］Mariano-Goulart D, Eberlé MC, Boudousq V, Hejazi-Moughari A, Piot C, et al. Major increase in brain natriuretic peptide indicates right ventricular systolic dysfunction in patients with heart failure［J］. Eur J Heart Fail, 2003, 5(4):481-488.
	［11］Costello JM, Backer CL, Checchia PA, Mavroudis C, Seipelt RG, Goodman DM. Alterations in the natriuretic hormone system related to cardiopulmonary bypass in infants with congestive heart failure［J］. Pediatr Cardiol, 2004, 25(4):347-353.
	［12］Nagaya N, Ando M, Oya H, Ohkita Y, Kyotani S, Sakamaki F, et al. Plasma brain natriuretic peptide as a non-invasive marker for efficacy of pulmonary thromboendarterectomy［J］. Ann Thorac Surg, 2002, 74(1):180-184.
	［13］Cauliez B, Berthe MC, Lavoinne A. Brain natriuretic peptide: physiological, biological and clinical aspects［J］. Ann Biol Clin (Paris), 2005, 63(1):15-25.
	［14］Heidrich FM, Zhang K, Estrada M, Huang Y, Giordano FJ, Ehrlich BE. Chromogranin B regulates calcium signaling, nuclear factor kappaB activity, and brain natriuretic peptide production in cardiomyocytes［J］. Circ Res, 2008, 102(10):1230-1238.
	［15］Tota B, Angelone T, Mazza R, Cerra MC. The chromogranin A-derived vasostatins: new players in the endocrine heart.Curr Med Chem［J］. 2008, 15 (14):1444-1451.
	［16］Langenickel T, Pagel I, Hohnel K, Dietz R, Willenbrock R. Differential regulation of cardiac ANP and BNP mRNA in different stages of experimental heart failure［J］. Am J Physiol Heart Circ Physiol, 2000, 278(5):H1500-1506.
	［17］Guerra MS, Roncon-Albuquerque R Jr, Lourenco AP, Falcao-Pires I, Cibrao-Coutinho P, Leite-Moreira AF. Remote myocardium gene expression after 30 and 120 min of ischaemia in the rat［J］. Exp Physiol, 2006, 91(2):473-480.
	［18］Frantz RP, Olson LJ, Grill D, Moualla SK, Nelson SM, Nobrega TP, et al. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure［J］. Am Heart J, 2005, 149(3):541-547.
	［19］Shyu KG, Liou JY, Wang BW, Fang WJ, Chang H. Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor1alpha and vascular endothelial growth factor in pressure-overloaded rat heart［J］. J Biomed Sci, 2005, 12(2):409-420.
	［20］Qvigstad E, Sjaastad I, B-kenes J, Schiander I, Solberg L, Sejersted OM, et al. Carvedilol blockade of alpha1-and beta-adrenoceptor induced inotropic responses in rats with congestive heart failure［J］．Eur J Pharmacol, 2005, 516(1):51-59.